Background. Whether the early reduction in cytomegalovirus (CMV) disease seen at 1 year
with prolongation of antiviral prophylaxis (up to 200 days) persists in the long term is …

The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus
(CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient …

Background. Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Preemptive treatment with antiviral agents of patients with CMV …

Background Recent studies have demonstrated that cytomegalovirus (CMV) infection and
disease are associated with increased risk of graft loss and death in high‐risk (donor CMV …

Recent developments in the diagnosis and therapy of cytomegalovirus (CMV) infection have
helped to reduce CMV-associated morbidity and mortality following allogeneic bone marrow …

Currently available, potent antiviral agents have proven highly effective for the prevention of
CMV disease during the time that prophylaxis is employed. However, late‐onset CMV …

Background. Rapid quantifiable diagnostic techniques for the diagnosis of cytomegalovirus
(CMV) infection may predict patients at risk of CMV pneumonitis and allow preemptive …

Background Valganciclovir is used to prevent posttransplant cytomegalovirus (CMV)
infection among patients undergoing kidney transplant. However, the optimal dose remains …

Background/objective: Prevention of cytomegalovirus (CMV) infection is an important
component of post kidney transplant care. We aimed to evaluate the impact of two different …

Cytomegalovirus (CMV) is a significant pathogen complicating the post‐transplant course of
organ recipients. In liver transplant patients, the febrile clinical illness caused by CMV may …